Summary
Efficacy of efalizumab in the treatment of patients with moderate to severe plaque psoriasis with hands/feet, scalp, and nails involvement: Results from a postapproval phase IIIb/IV study (control II)
Summary
Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)
Summary
Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)
Summary
Efficacy of efalizumab in the treatment of palmoplantar psoriasis in patients with moderate-to-severe plaque psoriasis: Results from a post-approval, phase IIIB/IV study (control II)
Summary
Efficacy of efalizumab in the treatment of scalp psoriasis in patients with moderate-to-severe plaque psoriasis: Results from a post-approval, phase IIIB/IV study (control II)
Summary
Safety of efalizumab in patients with moderate-to-severe plaque psoriasis: Results from a post-approval, phase IIIB/IV study (CONTROL II)
Summary
Efalizumab improves nail, scalp and palmoplantar psoriasis symptoms: Results from phase IIIB/IV clinical trial in patients from Latin American Countries with moderate-to-severe plaque psoriasis
Summary
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from extended treatment in an international, Phase III, placebo-controlled trial
Summary
Clinical benefits in patients with psoriasis after efalizumab therapy: Clinical trials versus practice
Summary
Clinical benefits in patients with psoriasis after efalizumab therapy: Clinical trials versus practice
This site complies with the HONcode standard for trustworthy health information: